Immunovant – Consensus Indicates Potential 132.8% Upside

Broker Ratings

Immunovant found using ticker (IMVT) now have 11 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 55 and 26 with a mean TP of 38.55. Now with the previous closing price of 16.56 this now indicates there is a potential upside of 132.8%. The day 50 moving average is 32.65 while the 200 day moving average is 39.66. The company has a market capitalisation of $1,562m. Find out more information at:

Immunovant, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant is a subsidiary of Roivant Sciences Ltd.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index